N/A N=8,299 The Effect of an Electronic Medical Record (EMR) Alert on Hepatitis B Screening
Hepatitis B
Primary: Serum Hepatitis B Surface Antigen Completion — 389; 177 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=100 A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors
Advanced Malignancies · Metastatic Cancer
Primary: Number of Participants With Any Treatment-Emergent Adverse Event (TEAE) and as Per the Severity — 4; 4; 4; 3 Participants
Phase 2 N=96 Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia
Accelerated Phase Chronic Myelogenous Leukemia · Adult Acute Lymphoblastic Leukemia in Remission · Adult Acute Myeloid Leukemia in Remission
Primary: Relapse Incidence — 18 Participants
N/A N=40 N6 Input Processing in Traditional CI Recipients
Hearing Loss
Primary: Endpoint 1: Evaluation of Signal to Noise Ratio - Noise Reduction — -5.9 difference in percent correct scores
N/A N=127 Deep Brain Stimulation (DBS) for the Suppression of Tremor
Tremor · Action Tremor · Essential Tremor
Primary: Primary Efficacy Endpoint: Difference in the Postural Tremor Score of the Target Limb Between Stimulation On and Stimulation Off, As Assessed by the Blind Reviewer…
Phase 3 N=98 TCR Alpha/Beta Depletion for HSCT From Haploidentical and Unrelated Donors in the Treatment of PID
Primary Immune Deficiency Disorder · Hematopoietic Stem Cell Transplantation
Primary: Overall Survival — 86; 86; 87 percentage of survival probability — p=0.95
Phase 3 N=72 Study to Assess the Efficacy of Liraglutide in Patients With Type 2 Diabetes Mellitus
Type 2 Diabetes
Primary: Changes From Baseline on Measurements of Respiratory Function Defined by Forced Expiratory Volume in 1 Second (FEV1) — 4.1; 4.3 % (FEV1)
Phase 3 N=456 Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
COPD
Primary: Percent Change From Baseline in BMD of the Lumbar Spine — -0.093; 0.379; -0.120 Percentage
Phase 3 N=627 Tanezumab in Osteoarthritis Of The Hip
Arthritis · Osteoarthritis · Osteoarthritis, Hip
Primary: Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Week 16: Baseline Observation Carried Forward…
N/A N=32 A Study of the Safety and Performance of the MINITAC◊ Titanium 2.0 Suture Anchor
Hallux Valgus Repairs · Medial or Lateral Instability Repairs/Reconstructions · Achilles Tendon Repairs/Reconstructions
Primary: Clinical Success Rate (%) of the MINITAC◊ Ti 2.0 Suture Anchor in Extremities at 6 Months Post-operative — 31 Participants
Phase 3 N=934 Bioequivalence Study With Clinical Endpoint for Diclofenac Sodium Topical Gel 1%
Osteoarthritis, Knee
Primary: Mean Change From Baseline to Week 8 in WOMAC Pain Scale, Bioequivalence of Test to Reference. — 6.8; 6.7; 5.9 units on a scale
Phase 1 N=24 A Phase 1 Study of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer
Colorectal Cancer
Primary: Dose Limiting Toxicity (DLT) — 0; 0; 0; 0 participants
N/A N=76 A Pilot Intervention to Improve Coping With Discrimination and Adherence Among HIV-Positive Latino MSM
HIV
Primary: Continuous Adherence (MEMS) — 86.7; 79.0; 85.5; 79.7 % of doses taken, past month — p=0.06
N/A N=34 Ketamine for Acute Migraine in the Emergency Department
Headache
Primary: Achievement of Pain Response After Ketamine Dose. — 2.0; 1.0 change in score on a scale
Phase 4 N=42 Intranasal Midazolam in Children as a Pre-Operative Sedative - Part 2
Sedation
Primary: Pediatric Pre-Induction Anesthesia Scale at Time of Mask Placement — 11; 3; 6; 1 Participants — p=0.39